Are You Interested in Targeting EJFR Activating Mutations?

I think that it's always interesting because we tend to associate targeted therapies with duration of response. But again, if you look at that data on data podum after oxygen, duration of response of 10 months or so is pretty respectable. And that was again in a true sort of salvage situation. So I think that you're right in terms of what our enthusiasm is. We tend to be enthusiastic about, for instance, dual checkpoint inhibition, modifying the immune response, things like that. But in my clinic, I want people to live longer and feel good. And I don't really care that much what the mechanism is as long as it achieves those goals.